Study of ABBV-291 for non-Hodgkin's lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug called ABBV-291 for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two previous treatments. The goal is to see how safe it is, how well it works, and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell lymphoma (like mantle cell lymphoma, follicular lymphoma, or diffuse large B-cell lymphoma) that needs treatment.
- Your cancer must have come back or not responded to at least two prior treatments, or you cannot take standard treatments.
- You must be willing to provide a tumor tissue sample (either from a past biopsy or a new one) for testing.
- You must be in generally good health, able to care for yourself and be up and about (ECOG score 0 or 1).
- You cannot have had certain other cancer treatments within 2 to 4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.